Pulmonary function of inhaled human insulin (Exubera®) in patients with type 2 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 742s Year: 2006
Pulmonary function tests in type 2 diabetes: a meta-analysis Source: ERJ Open Res, 7 (1) 00371-2020; 10.1183/23120541.00371-2020 Year: 2021
Effect of inhaled human insulin (EXUBERA®; EXU) vs subcutaneous insulin (SC) on lung lining fluid constituents in adults with type 1 diabetes mellitus (T1DM) Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Insulin therapy increases airway responsiveness in type 2 diabetes patients Source: Annual Congress 2008 - Cough and airway hyperresponsiveness Year: 2008
Centralised quality assurance (QA) for PFTs in a multi-center inhaled insulin trial Source: Annual Congress 2006 - Landmark developments in lung function testing: 2006 Year: 2006
Inhaled insulin does not induce immediate airway responsiveness in patients with type 1 diabetes mellitus Source: Eur Respir J 2005; 26: Suppl. 49, 582s Year: 2005
Effect of ICS on glycaemic control in patients with COPD and comorbid type 2 diabetes: Historical case-matched cohort study Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care Year: 2016
Longitudinal follow-up of pulmonary, nutritional and laboratory data in patients with cystic fibrosis related diabetes mellitus (CFRD) after initial treatment with glibenclamid Source: Eur Respir J 2003; 22: Suppl. 45, 229s Year: 2003
Long-term use of inhaled corticosteroids and the risk of type 2 diabetes in COPD Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases Year: 2020
Effect of roflumilast (ROF) on glucose levels in patients with COPD and diabetes mellitus type 2 (DM2) Source: Annual Congress 2010 - COPD: management Year: 2010
Decline of the lung function and quality of glycemic control in type 2 diabetes mellitus Source: Annual Congress 2013 –Novel biomarkers and old parameters in clinical management of lung diseases Year: 2013
FEV1 response to albuterol is not affected by inhaled human insulin (Exubera®) use in subjects with mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 840s Year: 2006
Characterizing the effects of inhaled human insulin (Exubera®) on FEV1 using disease progression modeling Source: Eur Respir J 2006; 28: Suppl. 50, 614s Year: 2006
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Death rate of COPD patients and combination with type 2 diabetes Source: Eur Respir J 2007; 30: Suppl. 51, 79s Year: 2007
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016